Oramed Pharm (ORMP) AI Stock Analysis

• Market Cap: $91.10M
• Dividend Yield: N/A
• Average Volume (3M): 75.52K
• Price to Earnings (P/E): 21.1
• Beta (1Y): 0.76
• Revenue Growth: -100.00%
• EPS Growth: N/A
• Country: US
• Employees: 13
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): -0.48
• Shares Outstanding: 40,850,456
• 10 Day Avg. Volume: 119,849
• 30 Day Avg. Volume: 75,520
• PEG Ratio: -0.51
• Price to Book (P/B): 3.09
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -16.51
• Enterprise Value/Market Cap: 4.72
• Enterprise Value/Revenue: 213.29
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: 6.69
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 47 Neutral
• Price Target: ―

Oramed Pharm's overall score is driven by a strong balance sheet but hindered by poor income and cash flow performance. Technical indicators are neutral, and the valuation is typical for the industry. The absence of earnings call data and significant corporate events leaves fundamental concerns unaddressed.

Positive Factors

Investment

The joint venture will receive a significant capital infusion, with HTIT committing a notable $70M investment, supplemented by a $20M investment from Oramed.

Joint Venture

Oramed entered into a definitive agreement with HTIT, marking a milestone in the creation of a joint venture centered around Oramed’s cutting-edge oral drug delivery technology.

Negative Factors

Clinical Efficacy

The candidates in Oramed's pipeline have yet to show definitive clinical proof-of-concept efficacy.

Oramed Pharm Business Overview & Revenue Model

Company Description

Oramed Pharmaceuticals Inc. (ORMP) is a clinical-stage pharmaceutical company focused on the development of innovative oral drug delivery solutions. The company operates primarily in the biotechnology sector, aiming to transform injectable treatments into oral alternatives. Its flagship product is an oral insulin capsule for the treatment of diabetes, which is designed to improve the quality of life for millions of diabetic patients worldwide.

How the Company Makes Money

Oramed Pharmaceuticals generates revenue primarily through the development and potential commercialization of its oral drug delivery technology. The company's revenue model is heavily reliant on successful clinical trials and the subsequent approval and licensing of its products. Oramed partners with pharmaceutical companies to co-develop and license its technologies, receiving milestone payments and royalties from these collaborations. Additionally, the company may engage in research and development service agreements, contributing to its revenue streams. However, as a clinical-stage company, its current earnings are mostly derived from partnerships and investments aimed at advancing its clinical programs.

Oramed Pharm Financial Statement Overview

Summary

Oramed Pharm's financial performance is mixed. The income statement is weak due to zero revenue and negative EBIT, while the balance sheet is strong with a high equity ratio. Cash flow is negative, indicating liquidity issues.

Income Statement

Oramed Pharm's income statement reflects significant challenges, primarily due to zero revenue in the TTM, a negative EBIT, and fluctuating net income figures. The lack of revenue growth and negative margins highlight ongoing operational inefficiencies.

Balance Sheet

The balance sheet shows a strong equity position with a high equity ratio, indicative of financial stability. However, the debt-to-equity ratio is low, providing some leverage risk, but overall liabilities remain manageable relative to equity.

Cash Flow

Cash flow analysis reveals negative operating and free cash flows, indicating potential liquidity issues. The operating cash flow to net income ratio is unfavorable, suggesting challenges in converting income into cash flow.

Breakdown
TTM	Dec 2023	Dec 2022	Sep 2021	Sep 2020	Sep 2019
Income Statement		Total Revenue
0.00	1.34M	2.70M	2.70M	2.71M	2.70M
	Gross Profit
0.00	1.34M	2.70M	2.70M	2.62M	2.61M
	EBIT
-13.06M	-15.77M	-40.60M	-24.22M	-11.76M	-14.63M
	EBITDA
24.86M	-15.57M	-36.98M	-25.04M	-11.31M	-14.17M
	Net Income Common Stockholders
4.46M	5.53M	-37.76M	-22.24M	-11.51M	-14.36M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
142.30M	162.05M	155.72M	94.14M	39.90M	32.28M
	Total Assets
165.08M	220.55M	161.64M	128.00M	44.63M	34.66M
	Total Debt
429.00K	51.62M	894.00K	533.00K	75.00K	0.00
	Net Debt
-41.67M	42.57M	-39.57M	-76.71M	-19.22M	-3.33M
	Total Liabilities
9.56M	57.66M	10.49M	11.48M	11.75M	15.27M
	Stockholders Equity
156.44M	163.82M	151.81M	115.77M	32.88M	19.39M
Cash Flow		Free Cash Flow
-7.93M	-10.55M	-28.41M	-21.56M	-12.52M	-12.96M
	Operating Cash Flow
-7.92M	-10.29M	-27.92M	-21.18M	-12.44M	-12.94M
	Investing Cash Flow
120.39M	-73.04M	30.21M	-23.76M	4.63M	11.26M
	Financing Cash Flow
-75.84M	51.98M	10.78M	102.89M	23.79M	0.00

Oramed Pharm Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.23
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ORMP, the sentiment is Positive. The current price of 2.23 is above the 20-day moving average (MA) of 2.20, above the 50-day MA of 2.22, and below the 200-day MA of 2.32, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 50.39 is Neutral, neither overbought nor oversold. The STOCH value of 52.27 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ORMP.

Oramed Pharm Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MNKD	63 Neutral	$1.19B	38.92	-35.00%	―	32.50%	236.33%
AMRN	58 Neutral	$265.61M	―	-17.22%	―	-22.93%	-65.68%
LGND	55 Neutral	$2.19B	48.01	-16.56%	―	53.40%	-230.86%
Sector *	54 Neutral	$5.38B	3.40	-45.06%	3.28%	16.75%	-0.02%
ORMP	47 Neutral	$91.10M	21.10	-18.37%	―	-100.00%	―
VSTM	44 Neutral	$336.29M	―	-2159.50%	―	―	14.39%
RDHL	41 Neutral	$4.65M	―	1155.92%	―	―	―